CBD and cannabis extracts reduced the effectiveness of platinum chemotherapy drugs in cell models

Even low concentrations of cannabinoids reduced the toxicity of cisplatin, oxaliplatin, and carboplatin in human cell cultures. The mechanism was not transcriptional but involved reduced intracellular platinum accumulation, suggesting cannabinoids impair cellular transport or retention of these drugs. This raises the possibility that cannabinoids used to counter chemotherapy side effects could simultaneously reduce chemotherapy effectiveness.

Preclinical study using human cell culture models. Cancer cells were treated with platinum-based drugs with and without CBD or cannabis extracts. Platinum adduct formation, molecular markers, trace metal analysis, and transcriptional profiling were used to determine the mechanism of interaction.

Many cancer patients use cannabinoids to manage chemotherapy side effects like nausea. If cannabinoids reduce how much chemotherapy drug reaches cancer cells, the very relief they provide could come at the cost of treatment effectiveness.

This preclinical finding raises an important clinical question: should cancer patients using platinum-based chemotherapy be counseled about potential interactions with cannabis products, even those used for symptom management?

Cell culture models do not account for whole-body pharmacokinetics. Concentrations tested may not reflect those achieved with typical human cannabis use. Did not test whether timing of cannabinoid and chemotherapy dosing affects the interaction.